Reckitt Wants Out of Mead Johnson at Almost Any Price. For Danone, the Infant-Formula Exit Is the Whole Point.

The boldest way to grow a consumer-goods company in the 2010s was to buy your way into a category you did not understand. The cleanest way to grow one in 2026 is to sell that purchase back at a loss and refocus. Reckitt is now doing exactly that. The owner of Durex, Finish and Dettol has put Mead Johnson — the infant-formula business it bought for almost $18 billion in 2017 — back on the market, and is seeking offers of around $7 billion by late May. A decade of ownership has erased more than half the value of one of the largest acquisitions in Reckitt's history. The question is no longer whether Reckitt overpaid. It is who will catch a falling asset — and the most credible answer is Danone.

A $17.9 billion bet that never paid off

Reckitt bought Mead Johnson in 2017 to push a cleaning-and-hygiene company into nutrition, betting that infant formula carried the same pricing power and brand loyalty as its core brands. It did not work as planned. The unit has been battered by impairments, disposals and a wave of US product-liability lawsuits, and today accounts for only about 15% of Reckitt's revenue — roughly £2.1 billion. Under chief executive Kris Licht, Reckitt has formally labelled Mead Johnson 'non-core' and rebuilt its strategy around a tighter set of hygiene and health Powerbrands. It has already sold Mead Johnson's Greater China formula business to Primavera Capital for $2.2 billion — a partial exit that made the full one look inevitable. So what? When a company marks its own trophy purchase down to roughly a third of what it paid, the sale is about focus, not price discovery.

The asset private equity will not touch

On paper, a $7 billion carve-out of a global brand with steady, repeat demand should draw every large buyout fund. In practice, only a handful of private-equity firms have followed through with bids. The reason is litigation: thousands of US claims allege that cow's-milk-based formula caused necrotising enterocolitis in premature infants, and juries have already returned large verdicts — including $60 million against Mead Johnson over Enfamil and $495 million against Abbott over its rival Similac. Open-ended legal exposure is exactly the tail risk financial buyers struggle to underwrite and lenders struggle to finance. That tilts the field toward a strategic buyer: a focused nutrition operator can carry the overhang against decades of synergies and category expertise, where a fund modelling a five-year exit cannot. So what? The litigation is not just a discount on the price — it is the moat that keeps cheap-money buyers out and hands the asset to whoever has the longest horizon.

What Danone actually gets

Danone is reported to be weighing a bid with advisers at Centerview Partners, and the rationale is clean. Specialised nutrition is core to Danone, not a diversification — and the United States is the one major market where it has never been strong in infant formula. Mead Johnson's Enfamil is one of the leading formula brands in America, the precise gap in Danone's global map. Bolt it on and Danone's existing strength across Latin America and Asia-Pacific starts to resemble genuine global leadership in a category controlled by a small group of players. The R&D, science and manufacturing synergies are real. So what? Danone would not be buying a struggling subsidiary. It would be buying the American foothold and the global scale that organic growth could never deliver fast enough.

The courtroom will set the price

Everything turns on the litigation calendar. A federal bellwether trial is set for July 2026, with state cases moving in parallel, and those verdicts — more than any revenue multiple — will set the clearing price. A buyer that can ring-fence the legal risk through indemnities or a litigation carve-out will win Mead Johnson; a buyer that cannot will walk. Reckitt's late-May deadline signals urgency, but a clean sale may still hinge on outcomes that land after it. The strategic logic can hold and the timetable can still slip.

What comes next

The Mead Johnson sale is a template for the next phase of Big Food and Big FMCG restructuring. The conglomerate diversification deals of the 2010s are being unwound, and the buyers are no longer the generalist private-equity funds that drove the last cycle — they are focused strategics able to carry risk that financial buyers will not. In 2026, the most valuable thing a buyer can own is not cheap capital but conviction in a single category. Watch whether Danone moves from exploration to a firm offer, whether a rival nutrition player or a litigation-comfortable fund breaks cover, and how the first verdicts reprice the asset. The deal that broke a hygiene conglomerate may yet build a nutrition champion.